5 December 2013 - The U.K.’s health-cost regulator has asked Sanofi for more information on its multiple-sclerosis drug Lemtrada (alemtuzumab), less than a month after U.S. regulatory advisers said the drug’s trials weren’t adequate to assess its efficacy. NICE is seeking clarifications on the evidence Paris-based Sanofi’s Genzyme unit submitted on the drug, NICE said in draft guidance today. Sanofi has until Jan. 9 to submit the extra information, the institute said. NICE, which advises the U.K.’s NHS on which treatments provide value for money, didn’t specify what information it requested.

For more details, go to: http://www.bloomberg.com/news/2013-12-05/u-k-cost-agency-seeks-more-lemtrada-data-from-sanofi.html